# Pymaceuticals, Inc. 

- Squamous Cell Carcinoma Study

Pymaceuticals, Inc. conducted a comprehensive animal study to evaluate potential treatments for squamous cell carcinoma, a prevalent form of skin cancer. The study involved 249 mice with SCC tumors, which were treated with a variety of drug regimens. Over a 45-day period, tumor development was closely monitored and measured. The primary objective of the study was to assess the efficacy of Pymaceuticals' drug of interest, Capomulin, in comparison to other treatment regimens.

